92043-13-5

Usage

Uses

Used in Medicinal Chemistry and Pharmaceutical Research:
[4-(2-methoxyphenyl)piperazin-1-yl]acetonitrile is utilized as a building block for the synthesis of various pharmaceuticals and biologically active molecules. Its piperazine moiety facilitates interactions with biological targets such as receptors, enzymes, and transporters, rendering it a valuable scaffold for drug design.
Used in Enhancing Lipophilicity and Solubility:
The presence of the acetonitrile group in [4-(2-methoxyphenyl)piperazin-1-yl]acetonitrile can improve the compound's lipophilicity and solubility, which may positively impact its pharmacokinetic properties and overall drug efficacy.

Upstream product

• 5464-78-8 1-(2-methoxyphenyl)piperazine hydrochloride 
• 590-17-0 cyanomethyl bromide 
• 380639-26-9 1-{[4-(2-methoxyphenyl)piperazin-1-yl]methyl}-1H-1,2,3-benzotriazole 
• 143-33-9 sodium cyanide 
• 35386-24-4 1-(2-Methoxyphenyl)piperazine 
• 107-14-2 chloroacetonitrile 

Relevant academic research and scientific papers

N-(4-[18F]-fluoropyridin-2-yl)-N-{2-[4-(2-methoxyphenyl) piperazin-1-yl]ethyl}carboxamides as analogs of WAY100635. New PET tracers of serotonin 5-HT1A receptors

N-(4-[18F]-Fluoropyridin-2-yl)-N-{2-[4-(2-methoxyphenyl) piperazin-1-yl]ethyl}-carboxamides were prepared by labeling their 4-nitropyridin-2-yl precursors through nitro substitution by the 18F anion. In vitro and in vivo tests showed

Synthesis and pharmacological evaluation of [(4-Arylpiperazin-1-yl)-alkyl]- carbamic acid ethyl ester derivatives as potential anxiolytic agents

On the basis of our earlier studies, a series of N-{4-[4-(aryl) piperazin-1-yl]-phenyl}-amine derivatives containing terminal carbamoyl fragment with alkyl spacer of different lengths (15-20) were synthesized as ligands, for 5-hydroxytryptamine-1A (5-HT1A

Synthesis, characterization and in vitro biological studies of novel cyano derivatives of N-alkyl and N-aryl piperazine

Cyano derivatives of N-alkyl and N-aryl piperazine have been synthesized and screened for antibacterial and antifungal activities. All the synthesized compounds showed the antibacterial activity against pathogenic strains of Staphylococcus aureus (MTCCB 737), Pseudomonas aeruginosa (MTCCB 741), Streptomyces epidermidis (MTCCB 1824) and Escherichia coli (MTCCB 1652) and antifungal activity against pathogenic strains of Aspergillus fumigatus (ITCC 4517), Aspergillus flavus (ITCC 5192) and Aspergillus niger (ITCC 5405). All compounds showed mild to moderate antimicrobial activity. However, compounds 3c, 4a and 6 showed potent antibacterial activity against pathogenic strains used in the study. Compounds 3a, 3b, 4b, and 4d showed mild to moderate antifungal activity against Aspergillus pathogenic strains. The compounds reported in this study were assessed for there cytotoxicity using MTT colorimetric assay on Hela cells. All the compounds showed cell viability more than the control drug gentamicin, with compound 2 having highest i.e. 95% cell viability.

Novel 5-HT7 receptor inverse agonists. Synthesis and molecular modeling of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides.

A series of arylpiperazine- and 1,2,3,4-tetrahydroisoquinoline-based arylsulfonamides was synthesized and evaluated for their interactions with the constitutively active 5-HT7 receptor. Effects on basal adenylate cyclase activity were measured using HEK-293 cells expressing the rat 5-HT7. All ligands produced a decrease of adenylate cyclase activity, indicative of their inverse agonism. Additionally, computational studies with a set of 22 inverse agonists, including these novel inverse agonists and inverse agonists known from literature, resulted in a pharmacophore model and a CoMFA model (R2 = 0.97, SE = 0.18). Docking of inverse agonists at the binding site of a model of the helical parts of the 5-HT7 receptor, based on the alpha carbon template for 7-TM GPCRs, revealed interesting molecular interactions and a possible explanation for observed structure-activity relationships.

Phenylpiperazinylalkylamino substituted pyridazinones as potent α1 adrenoceptor antagonists

QSAR models have been used for designing a series of compounds characterized by a N-phenylpiperazinylalkylamino moiety linked to substituted pyridazinones, which have been synthesized. Measurements of the binding affinities of the new compounds toward the

4-Bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2- naphthalenecarboxamides: Selective dopamine D3 receptor partial agonists

A series of 4-bromo-1-methoxy-N-[2-(4-aryl-1-piperazinyl)ethyl]-2- naphthalenecarboxamide dopamine (DA) D3 receptor agonists has been identified. These compounds were found to be selective for DA D3 over D2 receptors and were shown to be partial to full agonists as measured by stimulation of mitogenesis in D3-transfected CHO p-5 cells.

5-HT(1A), and D-2 receptor affinity of o-methoxyphenylpiperazine derivatives with terminal benzamide fragment on N-4 alkyl chain. 2

The synthesis of some o-methoxyphenylpiperazines with a benzamide moiety on N-4 alkyl chain was accomplished and their affinity for dopamine and serotonin receptor subtypes was assayed by in vitro receptor binding. The results show that several derivative